VA Studies Find Medical Pot Good for Nerve Pain

A recent research review found that medical marijuana may be effective at reducing chronic nerve pain, known as neuropathy, common among diabetes sufferers.

Dr. Sachin Patel of the Vanderbilt Psychiatric Hospital in Nashville said the findings on MMJ and neuropathy “fit generally well with what we know.”

In the second research review, both of which were commissioned by the U.S. Department of Veterans Affairs, researchers came up with less evidence that cannabis helps treat other types of pain or the effects of post-traumatic stress disorder (PTSD).

“That doesn’t mean that it’s not, it just means we don’t have that evidence right now,” said Patel.

The authors of the studies also decried the fact that there has not been enough high-quality research to produce conclusive evidence of the benefits or harms of cannabis for pain or PTSD.

There’s no way to come to conclusions based on the few studies currently available. But “several ongoing studies may soon provide important results,” the authors of the study wrote.

“The current studies highlight the real and urgent need for high-quality clinical trials in both of these areas,” Patel told Business Insider. “If cannabis is being considered for medical use, it should certainly be, after all, well-established treatments have failed.”

Earlier this year, the National Academy of Sciences released a report saying there is “conclusive” or “substantial scientific evidence” that marijuana is effective for treating chronic pain, calming muscle spasms caused by multiple sclerosis and easing nausea from chemotherapy.

Last May VA Secretary David Shulkin said at the White House that he was open to learning from any evidence that marijuana could be used as treatment, and that “there may be some evidence that this is beginning to be helpful.”

“And we’re interested in looking at that and learning from that,” Shulkin said. “But until the time that federal law changes, we are not able to be able to prescribe medical marijuana for conditions that may be helpful”

Although the VA commissioned the two studies, published in Annals of Internal Medicine, Curt Cashour, press secretary for the Department of Veterans Affairs, declined to make the lead study authors available for comment on their research, according to Business Insider.

Deputy director of NORML, Paul Armentano said the recent review findings are consistent with “anecdotal reports of patients, many of whom are seeking a safer alternative to the use of deadly opioids. And it is inconsistent with the federal government’s classification of the marijuana plant as a schedule I controlled substance with ‘no currently accepted medical use in treatment in the United States.’”

It is precisely the DEA’s intransigent and patently ludicrous labeling of cannabis as a dangerous drug that is hampering the scientific research that is sorely needed to convince the government what millions already know.

You can keep up with all of HIGH TIMES’ marijuana news right here.

Source link

Can Topical Cannabis Heal Wounds?

Photo by Justin Cannabis.

With vaping and edibles getting so much attention these days, let us not forget about the value and benefits of topical cannabis, like balms, lotions, oils and salves, that are showing remarkable results in healing skin wounds and abrasions, as well as easing muscular pain.

The cannabis plant contains over 90 unique chemicals, known as cannabinoids, with THC being the primary and best-known compound for obvious reasons, cannabidiol (CBD) is now recognized as the second compound of significance.

Recently, studies have found that topical CBD may be helpful in treating malignant wounds.

A case report published in the Journal of Pain and Symptom Management had this to say: “Anecdotal accounts of the use of topical extracts from the cannabis plant being used on open wounds date back to antiquity. In modern times, cannabinoid therapies have demonstrated efficacy as analgesic agents in both pharmaceutical and botanical formats.”

The combination of CBD and terpenes (the molecules that gives weed its distinct scent), according to the study, are what makes cannabis valuable in healing skin abrasions.

Medical cannabis patients have reported success with full extract cannabis oils when applied on to wounds caused by skin cancer or other illnesses.

Full extract cannabis oil is also called Rick Simpson Oil (RSO). Simpson became known around the world when he successfully treated his skin cancer lesions with cannabis oil.

Word to the wise: Before applying any topical products on broken or irritated skin, it is important to check whether they contain any harmful solvents or additives, including grain alcohol. Organic coconut oil and almond oil are widely considered to be safe for the skin.

Research published in 2008 also suggested that THC and CBD are effective antibiotics and have successfully killed severe strains of antibiotic resistant bacteria such as Staphylococcus aureus (MRSA), in the laboratory.

A study, published by the National Center for Biotechnology Information, posited that CBD may also be useful in treating acne abrasions.

“Collectively, our findings suggest that, due to the combined lipostatic, anti-proliferative, and anti-inflammatory effects, CBD has potential as a promising therapeutic agent for the treatment of acne vulgaris,” the study concluded.

And last but not least—muscular pain.

Ask just about any athlete, especially football players, or one of those 40 million Americans suffering from arthritis, CBD topical creams are well-known for their anti-inflammatory properties.

RELATED: 20 Must-Have Cannabis-Infused Body Products
You can keep up with all of HIGH TIMES’ marijuana news right here.

Source link

Feds to Study Curbing Opioid Epidemic with Medical Pot

The underbelly of the capitalist beast that is the United States government is working to get to the bottom of the claims that have surfaced over the past couple of years, suggesting that medical marijuana is effective at reducing opioid consumption in adults suffering from chronic pain.

It was revealed last week that the National Institutes of Health recently awarded a $3.8 million grant to the scientific minds at the Albert Einstein College of Medicine and Montefiore Health System to conduct a five-year investigation to determine whether cannabis medicine could be used as an alternative to prescription painkillers.

This is the first time Uncle Sam has ever coughed up a single cent to delve deeper into an increasing body of evidence pointing to cannabis as the trapdoor out of the opioid epidemic.

“There is a lack of information about the impact of medical marijuana on opioid use in those with chronic pain,” Chinazo Cunningham, M.D., M.S., associate chief of general internal medicine at Einstein and Montefiore, said in a statement. “We hope this study will fill in the gaps and provide doctors and patients with some much needed guidance.”

The study, which will consist of around 250 HIV positive and HIV negative patients presently enrolled in New York’s medical marijuana program, will examine pain reports in the form of “web-based questionnaires” to see with which medicine (cannabis or opioids) patients are experiencing the most success.

Researchers will also collect a series of blood and urine samples throughout the course of the next 18-months, as well as conduct “in-depth” interviews with the respondents to learn more about how they feel about the opioid versus medical marijuana debate.

Although President Trump announced last week that he was on the verge of declaring the opioid crisis a “national emergency,” his administration has not, so far, given any consideration to medical marijuana.

In fact, Trump, who suffered an embarrassing weekend for failing to condemn racist violence in Virginia, is reportedly considering “all things” with respect to putting a leash on the ongoing opioid problem, yet the idea of marijuana legalization seems to be missing from the equation.

Meanwhile, millions of people suffering from severe pain are leaning on opioid painkillers to make them feel human again—a situation that has caused a steady uptick in overdose deaths over the past 10 years.

Some of the latest data suggests that opioid deaths in hospital ICU’s have doubled since 2009.

An analysis from New York Times estimates that nearly 60,000 people died last year as a result of an opioid overdose.

Researchers hope their findings will lead to a solution.

“As state and federal governments grapple with the complex issues surrounding opioids and medical marijuana, we hope to provide evidence-based recommendations that will help shape responsible and effective healthcare practices and public policies,” Cunningham said.

You can keep up with all of HIGH TIMES’ marijuana news right here.

Source link

How Marijuana Can Help Treat Addictions to Opioids, Other Rx Drugs and Alcohol

Photo by Javier Hasse

This article was originally published on Benzinga, and adapted exclusively for HIGH TIMES.

People often talk about marijuana as an alternative to opioids and as a treatment for numerous addictions like alcohol and tobacco. But, like most praises (and condemnations) of weed, these claims are frequently based on hearsay rather than on actual science or quantitative evidence.

Max Simon, founder and CEO of Green Flower Media, the world’s largest platform for trusted cannabis education, is passionate about finding and sharing the science and data that supports the idea of cannabis enhancing people’s lives.

One of the qualities of cannabis is that it can help people get off diverse types of addictive pharmaceuticals, like opiates. The effect is double: Weed helps both with the pain and the resulting, underlying addiction to the medication.

“It’s amazing how cannabis works on the pain receptors to disrupt the pain signaling between the brain and the body,” Simon told Benzinga, pointing out that the duration of the therapeutic action of marijuana is equally remarkable, especially when consumed orally—in an edible format, basically.

In addition, cannabis can have a “forgetting effect,” psychopharmacologist and psychiatrist Julie Holland has argued.

“One of the benefits of cannabis as a medicine is that it stimulates a part of the brain that controls the memory, creating this forgetting effect, which can be quite profound for people who are trying to heal from addiction because it reduces the craving, it reduces the intensity of the memory of that dependence,” Simon added.

Of course, this is not to say that cannabis is innocuous, that it does not generate any kind of dependence—because it does. But, Simon’s argument is that, unlike highly addictive substances, “there is very conclusive evidence that the physical withdrawal symptoms related to cannabis are very minor for the vast majority of people.”

Now, to the actual figures.

According to recent CDC data, more than 33,000 Americans die from opioid overdoses every year. Still, doctors are prescribing them at alarming rates because, well, people are in pain—or so they say.

However, it is now known that cannabis can also have a notable effect on pain. In fact, the Drug Policy Alliance recently revealed that more than 70 percent of medical marijuana patients have felt “demonstrable and statistically significant pain relieving effects.”

On the other hand, most opioid-related deaths derive from the addiction that patients develop rather than from the search for pain relief. So, we know pot can help with pain, but can it help with addiction?

As per a study published in the Journal of the American Medical Association, opiate overdoses between 1999 and 2010 had decreased by 25 percent in states where medical marijuana was legal. Conversely, figures for states without medical cannabis are surging at alarming rates.

To establish some comparison, a recent study found that states that legalized medical cannabis before 2014 had seen 23 percent less opioid-induced hospital visits than those where marijuana remained illegal.

So, if you’re fighting with pain or addiction to any kind of prescription drugs, ask your doctor about the cannabis alternative, Simon explained.

For further info on how cannabis can help replace alcohol and prescription drugs, like Vicodin or Fentanyl, check out this Green Flower Media online class with UC Berkeley’s Amanda Reiman, PhD, and this one with Harvard-trained doctor Gregory L. Smith, MD, MPH.

More From Benzinga:
How Public Relations Firms Are Capitalizing On The Marijuana Green Rush
Largest Marijuana Dispensary Group In The US Now Takes Debit Payments
A Cannabis Wonderland? This Company Bought A Whole Town In California To Create A Marijuana Tourism Destination

You can keep up with all of HIGH TIMES’ marijuana news right here.

Source link

Report: Doctors Who Graduated from Harvard Prescribe Fewer Opioids

Physicians who studied medicine at Ivy League schools are less likely to prescribe opioid medications, according to a new working paper from the National Bureau of Economic Research.

A couple of economists from Princeton University have determined that doctors who graduated from some of the leading universities in the United States, specifically Harvard Medical School, are prescribing somewhere around three times fewer opioid painkillers than their counterparts hailing from a less prestigious alma-mater.

The research shows that doctors trained at Harvard wrote an average of 180 prescriptions for opioids every year, while physicians who graduated from lower ranked medical programs wrote 550 scripts annually during the same timeframe.

The study authors believe this phenomenon has everything to do with the level of training that is provided at the different schools.

“[T]he relationship between medical school rank and propensity to prescribe opioids persists even among specialists who attended different medical schools but practice in the exact same hospital or clinic—where patients can be assumed to be relatively homogenous in their need for opioids,” the researchers said. “[T]he relationship reflects the more rapid diffusion of best practices in top schools rather than the selection of certain types of physicians.”

Interestingly, researchers found that if all general practitioners, a group responsible for more than half the opioid prescriptions, subscribed to the same prescription pad philosophies as those coming out of Harvard, the number of opioids given to patients throughout the years would have diminished by more than half. What’s more is the mortality rate from overdoses could have, too, seen a sizable cut, which could have saved thousands of lives.

“Our results demonstrate that if all GPs prescribed like those from the top ranked school, we would have had 56.5 percent fewer opioid prescriptions and 8.5 percent fewer deaths over the period 2006 to 2014,” the paper shows.

A recent analysis from the New York Times shows that drug overdose deaths are increasing across the United States at a horrific rate. Their preliminary data revealed that nearly 60,000 people died last year as a result of an overdose to various drugs, a figure that represents the largest recorded death trend from the American addict daze that this country has ever seen.

At least half of these overdose deaths were the result of prescription drugs, according to the latest statistics from the Centers for Disease Control and Prevention.

Although the federal government recently introduced a new set of guidelines for doctors and pharmacists who dole out prescription opioids, the rules are not enforced in such a way to influence change. And while drug monitoring is now available in every state, the system has some serious design flaws, which makes it somewhat ineffective.

On the bright side, many medical schools are now starting to implement the federal government’s new opioid guidelines in their curriculum. An article from U.S. News & World Report indicates that 60 schools were set to adopt these changes by the fall of 2016.

You can keep up with all of HIGH TIMES’ news right here.

Source link

Study Shows Nearly Half of CBD Users Stop Taking Traditional Meds

A new survey, the largest to date, on cannabidiol (CBD) suggests that a growing number of patients are finding more relief from CBD than from traditional pharmaceuticals and they’re acting on this good news—especially the women.

Conducted by the Brightfield Group and HelloMD and covering 2,400 of HelloMD’s community of 150,000 members, the survey found that 55 percent of CBD users were women, while men preferred THC-dominant products.

The most common reasons people used CBD, according to Dr. Perry Solomon, the chief medical officer of HelloMD, were to treat insomnia, depression, anxiety and joint pain.

“We are seeing an exponential rise in the interest of CBD products from our patient community—particularly among women,” said Solomon. “While we still have much to learn about CBD, we cannot ignore this one fact; the majority of those using CBD products today receive great benefit. This has the potential for far-reaching consequences.”

Fully 42 percent of CBD users in the study said they had stopped using traditional medications like Tylenol, ibuprofen and stronger prescription (and addictive) pain relievers, after successfully switching to CBD, reported Forbes.

Eighty percent said that they found the products to be “very or extremely effective,” with only three percent saying they had felt little to no effect.

“This study is exciting because it shows there is potentially a huge barely-tapped market for CBD products that could improve the lives of many people,” said Bethany Gomez, director of research for Brightfield Group. “With further research and public education, CBD could be an effective alternative treatment for many people, particularly at a time when our nation is in the midst of an opioid crisis.”

Amen to that.

You can keep up with all of HIGH TIMES’ marijuana news right here.

Source link

Data Shows the Typical MMJ Consumer Is Upscale, Insured and Physician-Diagnosed

This article was originally published on Benzinga and adapted exclusively for HIGH TIMES.

With cannabis legalization across multiple states in the U.S. and other countries around the world, there’s been an explosion of research firms looking into the industry. ArcView Market Research became famous for its market-size predictions, Viridian Capital Advisors acquired notoriety for its Cannabis Deal Tracker and Cannabis Stock Index, and New Frontier Data gained a reputation for its extensive (collaborative) reports.

However, few analysts seem to have focused on the consumer-level to the extent that market researchers usually do in other industries. At least, that was the case until not too long ago, when Consumer Research Around Cannabis (CRAC) emerged, claiming to be “the only national research firm providing local consumer-level data for the emerging cannabis market.”

Unlike other firms out there, CRAC offers insights into cannabis users’ consumption habits and other non-marijuana-related conducts, like which cars they drive, how much they make per year, how much their houses are worth, what kind of insurance they have, etc.

As the data covers more than 85 markets in the U.S. and Canada, picking a topic and geography to hone into was both easy (in terms of options) and difficult—choices are hard.

Looking at some of the information and charts shared by vice president Jeff Stein, a data set caught Benzinga’s eye. It was the New York case.

About three months ago, the state of New York finally started permitting the prescription of medical marijuana for the treatment of chronic pain, adding the ailment to a short list that previously included only a few other conditions like epilepsy, HIV, AIDS and multiple sclerosis.

Following the policy adjustment, CRAC conducted consumer habits studies in the Buffalo and Albany metro areas, concluding that, “an estimated 46,668 adults in the heavily populated Buffalo-Niagara Falls metro area listed the ‘treatment of chronic pain’ as an important reason for their purchase of medicinal marijuana.”

Furthermore, CRAC said that in the smaller Albany-Schenectady-Troy Capital Region, the number reached 28,734 adults, taking the grand total above in just those two metro areas to more than 75,000 people.

What’s more interesting, though, is the deeper analysis of the responses, which counter-intuitively revealed that these medical cannabis users seeking relief of chronic pain are “upscale, insured and visit a variety physicians.”

“This target group is also growing due to the recent changes in state laws, representing a business growth opportunity in New York,” a recent report read.

Check out the figures for adults disclosing the use of cannabis for the treatment of chronic pain in three charts—sorted by income, insurance and physicians visited:

Intrigued by the New York state results, Benzinga reached out to CRAC and asked them to share similar information for other markets in order to find out if the trend of medical marijuana users in legal markets being upscale, insured and physician-diagnosed was confirmed.

“We can’t promise this will be the story in every city we look at because people are very different in each part of the country, but we have seen similar results in several other metro areas,” Stein told Benzinga, before sharing the additional data. “When we focus on the medical side of cannabis, it does seem to skew upscale, for the most part.”

However, not every market presented this over-indexing.

“We suspect that Phoenix’s large retiree population has something to do with employment info, and in Denver, the maturity of the marijuana market may be suppressing some of the indices since usage is much more common,” Stein commented. “An index reflects differences versus the average person in a market, so if it is more likely that the average person is using cannabis in Denver, the indexes will be closer to 100.”

More From Benzinga:
Public Marijuana Companies Using Stock To Make Acquisitions: What Does This Trend Mean For Investors?
Meet Avicanna, The First Marijuana Company To Be Accepted Into Johnson & Johnson Innovation, JLABS @ Toronto
Consumer Study Shows Which Cannabis Brands Are Winning The Design Race And Why

You can keep up with all of HIGH TIMES’ marijuana news right here.

Source link

First Walk-In Medical Marijuana Clinics Come to Florida

Medical marijuana has not been easy for Florida, despite the fact that fully 71 percent of the state’s population voted to approve it.

Florida’s MMJ laws, among of the most restrictive in the country, does not even allow for smoking it.

But have those 71 percenters in the Sunshine State given up? Hell no.

An experienced entrepreneurial woman decided to start up a few walk-in clinics for medical marijuana.

The clinics, known as the Tetra Health Centers, are the brainchild of Tracilea Young, who has opened six in Florida, one recently in Tampa, and plans to open 20 more across the state by next year, per CBS 10 News.

The clinics are not unlike walking into an urgent care center, except that you see a board-certified physician who is licensed to give MMJ recommendations. All doctors on hand are members of the Society of Cannabis Clinicians.

Young, president and founder of the California-based Tetra Health Clinics, saw an opportunity to expand in Florida.

“With such a high population of aging communities, medical marijuana is needed here,” Young said. “You wouldn’t believe the patients we see who come in here with Excel spreadsheets detailing all the medications they’re on and when they take which pill. I just want to cry for them.”

Young sees a business opportunity in being the intermediary between the Florida Department of Health and the companies licensed to grow and sell cannabis in the state, she told the Tampa Bay News.

She pointed out that visitors, however, should not expect to walk out with a baggie of weed. It doesn’t work that way.

At least patients can be seen by a physician, which is a detail that many newly-minted MMJ states are still struggling with under local and state restrictions.

Young says what she enjoys the most is seeing patients get freedom from medications.

Young opened the first Tetra Health Care clinic in her home state of California in 2015, when her former husband and father of her eight children was diagnosed with stage four throat cancer.

“It was an awful experience. He was so sick,” said Young. “So we opted for medical marijuana and were just so surprised with what the experience was like.”

Young said the first time she and her husband went to get a recommendation in California, they waited in a warehouse for hours. The doctor wrote the recommendation and quickly moved on to the other people waiting in line.

That’s when Young decided she wanted to provide a more professional and customer-centric experience for patients.

“We got into the business 19 years late in California,” she said. “But we’ve learned a lot. Our patient base is strictly medical. The level of care is what is most important to me.”

You can keep up with all of HIGH TIMES’ marijuana news right here.

Source link

From Great Smell to… Medical Benefits? The Truth about Terpenes

Photo by Jesse Faatz.

A new bar in Downtown Los Angeles is making cocktails spiked with terpenes that are also found in cannabis. There’s nothing wrong with adding an extra terp-kick to your drink, but advertising the terpene’s cancer benefits is a whole separate ball game. Is it any help that this new spot is called Prank Bar?

Prank Bar makes cocktails, such as the “Mon Frere,” a mix of Plymouth Gin Cocchi Americano, limonene terpenes and Regan’s Orange Bitter (I’m no mixologist, but isn’t it redundant to add limonene to a drink that already has orange bitters?), and their limonene-packed “Anti-Inflammatory” ambrosia. These drinks probably carry a powerful aroma, but don’t expect them to cure you of depression or cancer.

This whole terpene craze seemingly started with a review published in the British Journal of Pharmacology in 2011, titled, “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.” Written by Ethan Russo, a genuine pioneer in the field of cannabis science, this paper made quite a splash in the cannabis industry. After legalization progressed and labs popped up to analyze legal cannabis products for potency—and essential oil content—the terpene obsession really picked up.

Looking at data from different cannabis samples and trying to observe differences in terpene content between strains, some labs began making unsubstantiated claims regarding terpenes.

Indeed, the claim that myrcene, the main terpene in cannabis, somehow increases THC delivery to the brain is based on absolutely nothing, sorry folks. Nevertheless, connoisseurs began to demand higher terpene contents for the flavor, the “medical benefits” and this popular idea that terpenes modulate the effect of cannabinoids in the brain and are responsible for the perceived subjective effects of different strains.

Differences in cannabinoid content is a much more likely scenario for explaining the diverse effects of different cannabis strains—due to the proven and measurable effects these have on the brain.

However, the medical research that Russo used in his famous “entourage effect review is not hearsay from cannabis industry herbalists; in fact, he wrote the paper while serving as the senior medical adviser to GW Pharmaceuticals, the Big Pharma manufacturer of the cannabis drug Sativex.

For example, reported anti-anxiety properties of limonene are based on research done on mice using bitter orange extracts, which indeed show effects. But these mild observations cannot be directly translated to humans and often require very high doses. Limonene was also studied in a Phase I clinical trial for treating cancer, but has not yet advanced to Phase II. Similarly, myrcene has been studied for its pain-relieving properties, but conclusive evidence in humans has not been identified.

A review published this past January about the applications of terpenes for colorectal cancer indicated that terpenes may act as preventive agents, but their potential (not proven or even loosely indicated) cancer-fighting properties need further investigation.

Any mild medicinal benefits from terpenes in prevention of disease or induction of mild anti-anxiety effects can be best obtained from their natural sources. Want some of those limonene anti-anxiety effects? Eat an orange. Want the limonene gastro-esophageal benefits? Squeeze some lemon over your meal. The calming effects of caryophyllene? Sprinkle some oregano over your pizza.

The benefits of a vegetable-rich diet don’t just stem from vitamins and fiber, think of all the terpenes!

You can keep up with all of HIGH TIMES’ marijuana news right here.

Source link

Marijuana Could Help Treat Alzheimer’s: Here’s How It Would Work

This article was originally published on Benzinga and adapted exclusively for HIGH TIMES.

You’ve probably heard this before.

As early as 2008, several reports, including one published in the journal Molecular Pharmaceutics, began proposing various therapeutic pathways by which cannabinoids could treat Alzheimer’s Disease patients, but none were proven.

In 2014, a group of scientists made a breakthrough.

The conclusions of their pre-clinical study were published in the Journal of Alzheimer’s Disease, under the title, “The Potential Therapeutic Effects of THC on Alzheimer’s Disease.”

Put simply, “the paper argued that therapeutic, low [non-psychoactive] doses of THC (one of the main chemical compounds present in marijuana) could directly bind to a protein called amyloid-beta, preventing its aggregation and thereby slowing down the formation of amyloid-beta plaques around neurons,” Dr. Chuanhai Cao, a professor of neurology and pharmacy at the University of South Florida’s Byrd Institute for Alzheimer’s and lead researcher on the publication, told Benzinga.

Cannabis executive and IGC Inc. CEO Ram Mukunda said, “In Alzheimer’s Disease, beta-amyloid aggregates into a plaque-like substance that builds around the neurons and disrupts communication between them. So of course, if low-doses of THC can break up those plaques and prevent them from forming in the first place, it’s a huge breakthrough.”

While the results of the aforementioned studies were promising, two issues remained.

As one of the co-authors of the 2014 paper warned, “It’s important to keep in mind that just because a drug may be effective, doesn’t mean it can be safely used by anyone.” The evidence was still regarded as “anecdotal” by the scientific community, and conducting more thorough research often proved highly challenging due to the illegality of cannabis around the world.

But over the past few years, research around cannabis has grown.

Diverse clinical trials have begun to show that the side effects of THC and other cannabis compounds are tolerable to most patients and diminish over time. There is trial data showing that, at proper doses, cannabinoids have positive side effects for Alzheimer’s patients, such as a reductions in delusions and mood disorders.

The breakthrough research on the effect of THC for Alzheimer’s patients’ cognitive functions has also been validated in at least two papers.

One paper, published by the Salk Institute in 2016, directly validated the University of South Florida’s finding that low doses of THC break up amyloid-beta plaques on neurons. Another paper, published this year in Nature, confirmed the therapeutic promise, showing that cognitive function was restored in old mice who were given low doses of THC.

Not surprisingly, soon after discovering the pathway by which low-dose THC binds to amyloid-beta plaques and prevents them from aggregating on neurons, the University of South Florida filed a patent for that mechanism with the title “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.”

After months of negotiations with the University of South Florida, India Globalization Capital bought the exclusive rights to the U.S. patent filing, thereby “protecting a potential cannabis-based blockbuster treatment for America’s most expensive disease.”

“What IGC is going to do with this patent is take it to clinical trials,” Mukunda said. “We have productized it, and there is more than sufficient evidence. So, now we are now talking to several different places to see where we can begin clinical testing on the path to FDA approval.”

The company plans to test a few other endpoints for THC and Alzheimer’s, setting itself up as the only player with a strategy to take a cannabis-based Alzheimer’s drug to market. They’re still in need of additional funding.

Other companies like GW Pharmaceuticals PLC- ADR, Zynerba Pharmaceuticals and Insys Therapeutics are working on the treatment of other ailments like epilepsy, glaucoma and tumor cells with marijuana.

“[W]e are the only ones working on Alzheimer’s,” Mukunda said.

More From Benzinga:
Meet Avicanna, The First Marijuana Company To Be Accepted Into Johnson & Johnson Innovation, JLABS @ Toronto
How Marijuana Can Help Treat Addictions To Opioids, Other Rx Drugs And Alcohol
Nevada Marijuana Emergency Shows The Real Size Of America’s Demand For Cannabis

You can keep up with all of HIGH TIMES’ marijuana news right here.

Source link